Effects of an extract of serenoa repens on dogs with hyperplasia of the prostate gland

American Journal of Veterinary Research

Volumn 61, Issue 8, 2000, Pages 880-885

  Barsanti, Jeanne A ^a   Finco, Delmar R ^a   Mahaffey, Mary M ^a   Fayrer Hosken, Richard A ^a   Crowell, Wayne A ^a   Thompson Jr , Frederick N ^a   Shotts, Emmett B ^a,b  

^a UNIVERSITY OF GEORGIA   (United States)

^b LEETOWN SCIENCE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLANT EXTRACT; SABAL EXTRACT;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOG; HISTOLOGY; MALE; NONHUMAN; ORGAN WEIGHT; PROSTATE DISEASE; PROSTATE HYPERTROPHY; SEMEN ANALYSIS; TESTOSTERONE BLOOD LEVEL; TREATMENT OUTCOME;

EID: 0033898113     PISSN: 00029645     EISSN: None     Source Type: Journal    
DOI: 10.2460/ajvr.2000.61.880     Document Type: Article

References (43)

1. Isaacs JT. Common characteristics of human and canine benign prostatic hyperplasia. Prog Clin Biol Res 1984;145:217-234.
2. Matzkin H, Braf Z. Endocrine treatment of benign prostatic hypertrophy: current concepts. Urology 1991;37:1-16.
3. Berry SJ, Coffey DS, Walsh PC, et al. The development of human benign prostatic hyperplasia with age. J Urol 1984;132: 474-479.
4. Berry SJ, Strandberg JD, Saunders WJ, et al. Development of canine benign prostatic hyperplasia with age. Prostate 1986;9:363-373.
5. Brendler CB, Berry SJ, Ewing LL, et al. Spontaneous benign prostatic hyperplasia in the Beagle. J Clin Invest 1983;71:1114-1123.
6. Berry SJ, Coffey DS, Ewing LL. Effects of aging on prostate growth in Beagles. Am J Physiol 1986;250:R1039-R1046.
7. Zirkin BR, Strandberg JD. Quantitative changes in the morphology of the aging canine prostate. Anat Rec 1984;208:207-214.
8. Abramowicz M. Saw palmetto for benign prostatic hyperplasia (lett). Med Lett 1999;41:18.
9. Lepor H, Williford WO, Barry MJ, et al. The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. New Engl J Med 1996;335:533-539.
10. Oesterling JE. Benign prostatic hyperplasia. Medical and minimally invasive treatment options. New Engl J Med 1995;332: 99-109.
11. Walsh PC. Treatment of benign prostatic hyperplasia. New Engl J Med 1996;335:586-587.
12. Lowe FC, Fagelman E. Phytotherapy in the treatment of benign prostatic hyperplasia: an update. Urology 1999;53:671-678.
13. Buck AC. Phytotherapy for the prostate. Br J Urol 1996;78:325-336.
14. Marandola P, Jallous H, Bombardelli E, et al. Main phytoderivatives in the management of benign prostatic hyperplasia. Fitoterapia 1997;68:195-204.
15. Wilt JT, Ishani A, Stark G, et al. Saw palmetto extracts for treatment of benign prostatic hyperplasia: a systematic review. JAMA 1998;280:1604-1609.
16. DeKlerk DP, Coffey DS, Ewing LL, et al. Comparison of spontaneous and experimentally induced canine prostatic hyperplasia. J Clin Invest 1979;64:842-849.
17. Marks LS, Tyler VE. Saw palmetto extract: newest (and oldest) treatment alternative for men with symptomatic benign prostatic hyperplasia. Urology 1999;53:457-461.
18. Plosker GL, Brogden RN. Serenoa repens (Permixon): a review of its pharmacology and therapeutic efficacy in benign prostatic hyperplasia. Drugs Aging 1996;9:379-395.
19. Carilla E, Briley M, Fauran F, et al. Binding of Permixon, a new treatment for prostatic benign hyperplasia, to the cytosolic androgen receptor in the rat prostate. J Steroid Biochem 1984;20:521-523.
20. Sultan C, Terraza A, Devillier C, et al. Inhibition of androgen metabolism and binding by a liposterolic extract of "Serenoa repens B" in human foreskin fibroblasts. J Steroid Biochem 1984;20:515-519.
21. Iehle C, Delos S, Guirou O, et al. Human prostatic steroid 5 alpha-reductase isoforms - a comparative study of selective inhibitors. J Steroid Biochem Mol Biol 1995;54:273-279.
22. Elghamry MI, Hansel R. Activity and isolated phytoestrogen of shrub palmetto fruits (Serenoa repens small), a new estrogenic plant. Experientia 1969;25:828-829.
23. Di Silverio F, D'Eramo G, Lubrano C, et al. Evidence that Serenoa repens extract displays an antiestrogenic activity in prostatic tissue of benign prostatic hypertrophy patients. Eur Urol 1992;21:309-314.
24. Rhodes L, Primka RL, Berman C, et al. Comparison of finasteride (Proscar), a 5-alpha reductase inhibitor, and various commercial plant extracts in in vitro and in vivo 5-alpha reductase inhibition. Prostate 1993;22:43-51.
25. Strauch G, Perles P, Vergult G, et al. Comparison of finasteride (Proscar) and Serenoa repens (Permixon) in the inhibition of 5-alpha reductase in healthy male volunteers. Eur Urol 1994;26:247-252.
26. Fitzpatrick JM. Phytotherapy for treatment of benign prostatic hyperplasia: case not proven. Urology 1999;53:462-464.
27. Carraro JC, Raynaud JP, Koch G, et al. Comparison of phytotherapy (Permixon) with finasteride in the treatment of benign prostatic hyperplasia: a randomized international study of 1,098 patients. Prostate 1996;29:231-240.
28. Descotes JL, Rambreaud JJ, Deschaseaux P, et al. Placebo-controlled evaluation of the efficacy and tolerability of Permixon in benign prostatic hyperplasia after exclusion of placebo responders. Clin Drug Invest 1995;5:291-297.
29. Brooks JR, Berman C, Garnes D, et al. Prostatic effects induced in dogs by chronic or acute administration of 5-alpha reductase inhibitors. Prostate 1986;9:65-75.
30. Cohen SM, Taber KH, Malatesta PF, et al. Magnetic resonance imaging of the efficacy of specific inhibition of 5 alpha reductase in canine spontaneous benign prostatic hyperplasia. Magn Reson Med 1991;21:55-70.
31. Grasso M, Montesano A, Buonaguidi A, et al. Comparative effects of alfuzosin versus Serenoa repens in the treatment of symptomatic benign prostatic hyperplasia. Arch Esp Urol 1995;48:97-103.
32. Barsanti JA. Diseases of the prostate gland. In: Osborne CA, Finco DR, eds. Canine and feline nephrology and urology. Philadelphia: Lea & Febiger, 1995;726-758.
33. Cartee RE, Rumph PF, Kenter DC, et al. Evaluation of drug-induced prostatic involution in dogs by transabdominal B-mode ultrasonography. Am J Vet Res 1990;51:1773-1778.
34. Cohen SM, Werrmann JG, Rasmusson GH, et al. Comparison of the effects of new specific azasteroid inhibitors of steroid 5 alpha-reduclase on canine hyperplastic prostate: suppression of prostatic DHT correlated with prostate regression. Prostate 1995;26:55-71.
35. Laroque PA, Prahalada S, Monon-Noblot S, et al. Quantitative evaluation of glandular and stromal compartments in hyperplastic dog prostates: effect of 5-alpha reductase inhibitors. Prostate 1995;27:121-128.
36. Laroque PA, Prahalada S, Gordon LR, et al. Effects of chronic oral administration of a selective 5 alpha reductase inhibitor, finasteride, on the dog prostate. Prostate 1994;24:93-100.
37. Kamolpatana K, Johnston SD, Hardy SK, et al. Effect of finasteride on serum concentrations of dihydrotestosterone and testosterone in three clinically normal sexually intact adult male dogs. Am J Vet Res 1998;59:762-764.
38. Rittmaster RS. Finasteride. N Engl J Med 1994;330:120-125.
39. Bamberg-Thalen B, Linde-Forsberg C. Treatment of canine benign prostatic hyperplasia with medroxyprogesterone acetate. J Am Anim Hosp Assoc 1993;29:221-226.
40. Olson PN, Wrigley RH, Thrall MA, et al. Disorders of the canine prostate gland: pathogenesis, diagnosis, and medical therapy. Compend Contin Educ Pract Vet 1987;9:613-623.
41. Orima H, Shimizu M, Tsutsui T, et al. Short-term oral treatment of canine benign prostatic hypertrophy with chlormadinone acetate. J Vet Med Sci 1995;57:139-141.
42. Read RA, Bryden S. Urethral bleeding as a presenting sign of benign prostatic hyperplasia in the dog: a retrospective study (1979-1993).; Am Anim Hosp Assoc 1995;31:261-267.
43. Shimizu M, Tsutsui T, Kawakami E, et al. Effect of chlormadinone acetate-pellet implantation on the volume of prostate, peripheral blood levels of sex hormones, and semen quality in the dog. J Vet Med Sci 1995;57:395-399.